DavidBrianKarpfMD

Summary

• Dr. David Karpf is an experienced endocrinologist based in Palo Alto, CA with subspecialties in diabetes, lipid metabolism, osteoporosis, and bone metabolism medicine. He completed his fellowships in Endocrinology, Diabetes, and Metabolism at UCLA-VA Greater Los Angeles and Cedars-Sinai Medical Center, after his residency at the latter institution and gaining his medical degree from The University of California San Diego School of Medicine. He then undertook an elective 3rd year of fellowship to gain additional experience in metabolic bone diseases at the Endocrine Unit at UC San Francisco School of Medicine. Following 5 years on the UCSF Endocrine Faculty, Dr. Karpf was recruited to Merck to Merck & Co, Inc., to designed and run the Phase 3 fracture endpoint trials with Fosamax. Following the launch of Fosamax, Dr. Karpf was recruited to Roche based in Palo Alto, to initially work on an anabolic osteoporosis drug and then to run the Phase 3 fracture endpoint trials for both oral and IV Boniva. In 1997 Dr. Karpf joined the Stanford Endocrine Faculty, where he currently serves as Adjunct Clinical Professor of Endocrinology, Gerontology, and Metabolism at Stanford University School of Medicine, and Attending, Osteoporosis & Metabolic Bone Disease Clinic. He has a rich publication history, including influential work on osteoporosis, growth hormone deficiency and hypoparathyroidism. He has also participated in multiple clinical trials in related areas. His contributions have been recognized with numerous awards such as the Fellow from ASBMR in 2020 and the NIH FIRST Award in 1991.